Polyethylene Oxide (PEO) as a Pharmaceutical Excipient
What is Polyethylene oxide?
Polyethylene oxide (PEO) is a water-soluble, non-ionic polyether polymer composed of repeating ethylene oxide units. It has the same basic chemical repeat structure as polyethylene glycol (PEG), but the terms are conventionally used for different molecular-weight ranges and pharmaceutical applications. PEO generally refers to much higher-molecular-weight polymers, whereas PEG is more commonly used for lower- and intermediate-molecular-weight materials.
Pharmaceutical PEO grades are available over a broad molecular-weight range, extending from approximately 100,000 to several million g/mol. Increasing molecular weight strongly affects properties such as solution viscosity, polymer-chain entanglement, hydration, swelling, gel formation and erosion. These characteristics make high-molecular-weight PEO particularly useful as a hydrophilic matrix-forming polymer for modified- and controlled-release drug products.
When exposed to aqueous media, PEO hydrates and can form a viscous gel layer around a dosage form. Drug release may subsequently be governed by a combination of water penetration, polymer swelling, drug diffusion and polymer erosion. The relative contribution of these mechanisms depends on factors including PEO molecular weight and molecular-weight distribution, polymer concentration, formulation composition, tablet properties and the characteristics of the dissolution medium.
For pharmaceutical development, PEO should therefore not be considered solely in terms of its nominal grade or viscosity specification. Differences in molecular weight, molecular-weight distribution, hydration, swelling, erosion and degradation behaviour can be relevant to its functionality and to the performance of the finished drug product.
Polyethylene Oxide Characterization Services
Excipia Excipia provides specialized polyethylene oxide (PEO) analysis and characterization to investigate differences between grades, suppliers and batches that may not be apparent from routine Certificate of Analysis data.
We can characterize molecular-weight distribution, viscosity, hydration and swelling behaviour, physicochemical properties and polymer degradation, helping to understand PEO characteristics that may influence processing, gel formation, erosion and drug release.
Our experts can support PEO grade and supplier selection, batch comparison, formulation troubleshooting and the definition of additional specifications or Functionality Related Characteristics (FRCs) where appropriate.
Physicochemical Properties of Polyethylene Oxide
Polyethylene oxide is a hydrophilic, non-ionic polymer whose physicochemical properties depend strongly on molecular weight and molecular-weight distribution. Pharmaceutical PEO grades can therefore show substantial differences in solution viscosity, hydration, swelling, gel formation and erosion behaviour.
Water Solubility and Hydration
PEO is soluble in water and hydrates readily when exposed to aqueous media. For high-molecular-weight grades, dissolution of the polymer is preceded by water uptake, polymer-chain relaxation and swelling, resulting in the formation of a highly hydrated and viscous polymer layer. This hydration behaviour is particularly important in pharmaceutical matrix systems. The rate at which water penetrates the dosage form and the polymer hydrates influences the development and properties of the gel layer through which a drug may subsequently diffuse. [2,3]
Viscosity and Molecular Weight
The viscosity of aqueous PEO solutions increases strongly with increasing polymer molecular weight and concentration. High-molecular-weight PEO grades can produce highly viscous solutions and strong hydrated gel layers even at relatively low polymer concentrations. Viscosity is therefore an important characteristic of pharmaceutical PEO, but it does not provide a complete description of the polymer. Materials with comparable viscosity specifications may differ in molecular-weight distribution and the relative proportions of shorter and longer polymer chains, potentially affecting hydration, swelling, erosion and processing behaviour. [1,4]
Swelling, Gel Formation and Erosion
When PEO-containing matrices are exposed to aqueous media, the polymer absorbs water and swells. As hydration progresses, polymer chains become increasingly mobile and a gel layer develops around the dosage form. The behaviour of this layer reflects a balance between polymer hydration and swelling on the one hand and dissolution and erosion of polymer chains on the other. Molecular weight is particularly important: higher-molecular-weight PEO generally produces greater chain entanglement and more persistent gel structures, whereas lower-molecular-weight material can dissolve and erode more readily. These properties are central to the use of PEO in modified-release formulations because changes in gel-layer formation and erosion can alter the rate and mechanism of drug release. [1-3]
Thermoplastic Behaviour
PEO is a thermoplastic polymer and can be processed using techniques involving heat and mechanical energy. This property has supported its use in pharmaceutical processing approaches such as hot-melt extrusion and other thermally processed formulations. Processing conditions should nevertheless be considered carefully because temperature, shear and exposure to oxygen can affect polymer properties and may contribute to degradation, particularly under sufficiently severe processing or storage conditions.
Polyethylene oxide manufacturing
Polyethylene oxide is produced by the ring-opening polymerization of ethylene oxide. Depending on the polymerization conditions and catalyst system, polymers covering a broad range of molecular weights can be produced. The very high molecular weights characteristic of pharmaceutical PEO distinguish these materials from the lower-molecular-weight polyethers conventionally referred to as polyethylene glycols (PEGs).
The molecular characteristics of the resulting polymer are determined during polymerization. Parameters such as catalyst system, reaction conditions, monomer purity, temperature and control of chain initiation, propagation and termination can influence polymer molecular weight and molecular-weight distribution.
This is particularly relevant for pharmaceutical PEO because many of its functional properties are molecular-weight dependent. Molecular weight and molecular-weight distribution influence solution viscosity, chain entanglement, hydration, swelling, gel formation, polymer dissolution and erosion. Consequently, differences in polymer manufacture that result in different molecular characteristics can potentially translate into differences in pharmaceutical performance.
Following polymerization, the material must be recovered and processed into a suitable physical form. Subsequent processing can influence characteristics such as particle size and particle-size distribution, bulk properties, moisture content and thermal history. These characteristics can be relevant to powder handling, blending, compaction and hydration of the polymer in the finished dosage form.
Commercial pharmaceutical PEO is therefore supplied in a range of grades characterized by properties such as nominal molecular weight and solution viscosity. However, a nominal grade designation does not fully describe the polymer. Molecular-weight distribution, physical properties and degradation state can provide additional information when comparing PEO from different grades, batches or suppliers.
Synthesis Route of Polyethylene Oxide
The synthesis of PEO proceeds through ring opening of the three-membered ethylene oxide ring followed by successive addition of ethylene oxide units to the growing polymer chain. The resulting polymer has the repeating structure:
Figure 1 Structural formula of polyethylene oxide where n represents the number of repeating ethylene oxide units in the polymer chain.
The synthesis of polyethylene oxide can be described by the following principal steps:
- Initiation: Polymerization is initiated through a suitable catalyst or initiator system. Different catalytic systems can be used depending on the polymerization process and the molecular-weight range to be produced.
- Propagation: Ethylene oxide molecules undergo ring opening and are added sequentially to the growing polymer chain. Repeated propagation produces the long polyether chains characteristic of PEO.
- Termination and molecular-weight control: Chain growth is eventually terminated or stopped under controlled process conditions. The balance between initiation, propagation and termination contributes to the molecular weight and molecular-weight distribution of the resulting polymer.
For high-molecular-weight PEO, a very large number of ethylene oxide units are incorporated into each polymer molecule. However, the individual polymer chains within a commercial PEO material are not all identical in length. PEO is therefore characterized by a molecular-weight distribution (MWD) rather than by one discrete molecular weight.
The distribution can be described using parameters such as the number-average molecular weight (Mn), weight-average molecular weight (Mw) and dispersity (Mw/Mn). Two PEO materials can consequently have a similar nominal molecular weight while differing in the relative proportions of shorter and longer polymer chains.
These differences can be pharmaceutically relevant because polymer chain length and molecular-weight distribution influence chain entanglement, solution viscosity, hydration, swelling, gel formation, polymer dissolution and erosion. Characterization of the molecular-weight distribution can therefore provide information beyond nominal molecular weight or viscosity alone.
Polyethylene Oxide Grades and Molecular Weight
Pharmaceutical polyethylene oxide is available in a range of grades covering molecular weights from approximately 100,000 to several million g/mol. Commercial grades are commonly differentiated by nominal molecular weight and the viscosity of aqueous polymer solutions. As molecular weight increases, the polymer chains become longer and increasingly entangled, resulting in substantial changes in solution viscosity, swelling, gel formation and erosion behaviour. [1-4]
The molecular weight of PEO is particularly important for its use in pharmaceutical formulations. Lower-molecular-weight grades hydrate and dissolve relatively rapidly, whereas higher-molecular-weight grades generally form more viscous and persistent hydrated polymer layers. This provides formulators with a means of modifying the behaviour of hydrophilic matrices by selecting the appropriate PEO grade or by combining grades with different molecular weights.
However, the nominal molecular weight of a PEO grade represents only an average description of the polymer population. Commercial PEO consists of polymer chains with a distribution of molecular weights. Consequently, two materials with similar nominal molecular weight or apparent viscosity do not necessarily have identical molecular-weight distributions.
Molecular-Weight Distribution and Polydispersity
Molecular-weight distribution (MWD) describes the relative amounts of polymer chains of different lengths within a PEO material. It can be characterized using parameters such as number-average molecular weight (Mn), weight-average molecular weight (Mw) and dispersity (Mw/Mn).
The importance of molecular-weight distribution extends beyond analytical characterization. The relative proportions of shorter and longer polymer chains can influence the balance between polymer hydration, chain entanglement, swelling, dissolution and erosion. A broad or altered molecular-weight distribution may therefore produce polymer behaviour that cannot be predicted completely from nominal molecular weight alone.
Experimental studies with PEO matrices have shown that molecular weight has a pronounced effect on polymer swelling and erosion, while the influence of polydispersity can be more complex and depends on the composition and distribution of polymer chain lengths. This is important when interpreting differences between grades or suppliers: a difference in molecular-weight distribution should not automatically be assumed to result in different drug-product performance, but it can be an important material characteristic to investigate when unexplained differences occur. [1]
Molecular-Weight Distribution by SEC
Size-exclusion chromatography (SEC) can be used to characterize the molecular-weight distribution of PEO and compare polymer profiles between grades, suppliers and batches. In contrast to a single viscosity measurement, SEC provides information about the distribution of polymer chain sizes and can reveal changes in the polymer population.
SEC can therefore be particularly useful for:
- comparing PEO grades with similar nominal molecular weight or viscosity;
- evaluating differences between suppliers or batches;
- detecting shifts toward lower molecular weight resulting from polymer degradation;
- investigating unexpected changes in swelling, erosion or drug release;
- supporting the definition of additional material specifications or Functionality Related Characteristics (FRCs) where appropriate.
For pharmaceutical PEO, molecular-weight characterization can therefore provide an important link between polymer structure and functional performance.
Hydration, Swelling and Gel Formation of Polyethylene Oxide
When a PEO-containing dosage form comes into contact with an aqueous medium, water penetrates the polymer matrix and hydrates the PEO chains. Hydration increases polymer-chain mobility and causes the polymer to swell and form a viscous gel layer at the surface of the dosage form.
As water penetrates further into the matrix, different regions can develop between the dry tablet core and the surrounding dissolution medium. Polymer closer to the dry core is only partially hydrated, while the outer regions contain increasingly mobile and hydrated polymer chains. At the outer surface, sufficiently hydrated chains can disentangle from the polymer network and enter the surrounding medium, resulting in polymer dissolution and erosion. [1–3]
The development and persistence of this hydrated layer depend strongly on PEO molecular weight, molecular-weight distribution and polymer concentration. Higher-molecular-weight PEO generally provides greater chain entanglement and forms more persistent gel structures, whereas lower-molecular-weight material can hydrate, disentangle and erode more rapidly. [1–3]
Swelling and Polymer Erosion
Swelling and erosion occur simultaneously and their relative rates can change during dissolution. Water uptake causes expansion of the polymer matrix, while polymer loss from the outer hydrated layer reduces matrix dimensions. The dimensions of a PEO matrix during dissolution therefore reflect the dynamic balance between water penetration, polymer swelling and polymer erosion.
PEO molecular weight can substantially influence this balance. Studies comparing PEO materials of different molecular weights have demonstrated differences in matrix swelling, gel-layer development and polymer erosion. However, molecular weight alone does not determine behaviour; formulation composition and the distribution of polymer chain lengths can also influence the evolution of the hydrated matrix.
The polymer concentration in the formulation is also important. A sufficiently interconnected PEO network is required to maintain a coherent hydrated matrix. At lower polymer concentrations, the polymer network may be less continuous and erosion or disintegration can become more important. At higher concentrations, chain entanglement and formation of a continuous gel structure generally become more pronounced. [3]
PEO in Modified- and Controlled-Release Formulations
The combination of rapid hydration, high solution viscosity, swelling, gel formation and controllable erosion makes high-molecular-weight PEO particularly useful as a hydrophilic matrix polymer for modified- and controlled-release dosage forms.
After hydration of a PEO matrix tablet, drug molecules must move through or be released from the evolving hydrated polymer layer. Drug release can occur through several mechanisms acting simultaneously:
- diffusion of dissolved drug through the hydrated polymer network;
- polymer swelling and relaxation;
- erosion or dissolution of the PEO matrix;
- and, for poorly soluble compounds, release associated with loss of the surrounding polymer matrix.
The relative importance of these mechanisms depends on both the polymer and the drug. The relative contribution of diffusion and matrix erosion depends on factors including drug solubility, polymer molecular weight and formulation composition. Consequently, the same PEO material does not necessarily provide the same release mechanism for every drug substance. [2,5,6,7]
Influence of PEO Molecular Weight on Drug Release
Increasing PEO molecular weight generally increases chain entanglement and the viscosity and persistence of the hydrated polymer layer. This can reduce polymer erosion and alter diffusion through the matrix. Lower-molecular-weight PEO generally disentangles and dissolves more readily and can therefore produce a greater contribution from erosion. [1,2,4]
Selection of PEO grade is consequently an important formulation variable in controlled-release development. Blends of different PEO molecular-weight grades can also be used to modify matrix hydration and erosion behaviour and thereby adjust the resulting drug-release profile. [1,5,6]
Importantly, nominal viscosity or molecular-weight grade alone may not completely describe these properties. Differences in molecular-weight distribution, formulation composition, tablet structure and processing history can influence how a PEO matrix hydrates and erodes.
Formulation and Dissolution Conditions Affecting PEO Matrix Behaviour
PEO performance should be evaluated in the context of the complete formulation and the conditions under which drug release occurs. Relevant variables can include:
- PEO grade, molecular weight and molecular-weight distribution;
- PEO concentration and combinations of different grades;
- drug solubility and drug loading;
- other excipients and soluble or insoluble matrix components;
- tablet porosity, hardness and compaction conditions;
- ionic strength and composition of the dissolution medium;
- pH and other medium characteristics;
- temperature and hydrodynamic conditions.
Interactions between these variables can alter water penetration, polymer hydration, gel strength, swelling, erosion and drug diffusion. This is one reason why apparently similar PEO materials may need to be evaluated within the actual formulation rather than solely by comparing their Certificate of Analysis specifications. [3,5,6]
Stability and Degradation of Polyethylene Oxide
Polyethylene oxide is susceptible to oxidative degradation, which can result in cleavage of the polymer backbone and a reduction in molecular weight. Because many important pharmaceutical properties of PEO depend strongly on polymer molecular weight, degradation can affect not only the chemical stability of the excipient but also its viscosity, swelling, gel formation, erosion and controlled-release behaviour. [6,7]
Oxidative degradation of PEO can proceed through radical reactions involving the polyether chain. Formation of hydroperoxide intermediates can ultimately lead to polymer-chain scission and the formation of lower-molecular-weight polymer fragments and degradation products. Exposure to oxygen, elevated temperature, light and certain metal ions can promote these processes.
Molecular-Weight Changes During PEO Degradation
A particularly important consequence of PEO degradation is a shift in its molecular-weight distribution toward lower molecular weights. Such changes may be detected by size-exclusion chromatography (SEC) and can also result in a reduction in solution viscosity.
This is pharmaceutically relevant because shorter polymer chains generally show less chain entanglement and can dissolve or erode more readily than the original high-molecular-weight polymer. Degradation may therefore alter the formation and persistence of the hydrated gel layer in a PEO matrix.
A material can consequently remain identifiable as PEO while its molecular characteristics and functional behaviour have changed. For investigations of PEO stability, measurement of polymer molecular weight or molecular-weight distribution can therefore provide information that is not obtained from identification testing alone.
Influence of Processing and Storage
PEO can encounter conditions during pharmaceutical manufacturing that may influence its stability. Depending on the formulation and process, relevant stresses can include heat, mechanical shear, oxygen exposure and contact with other formulation components.
Thermal processing is particularly relevant when PEO is used in technologies such as hot-melt extrusion. Processing conditions should therefore be selected with consideration of both the required thermoplastic behaviour of the polymer and the possibility of molecular degradation.
Changes can also occur during storage. Temperature, oxygen exposure, moisture conditions, storage duration and interactions with other formulation components may influence polymer stability. The importance of these factors depends on the particular PEO grade, formulation, packaging and storage conditions.
Why PEO Degradation Can Affect Drug Release
For a PEO controlled-release matrix, polymer stability and dissolution performance are closely connected. A decrease in molecular weight can reduce polymer-chain entanglement, alter gel-layer properties and increase polymer erosion. These changes can potentially result in a different drug-release profile even when the nominal amount of PEO in the formulation has not changed. [7]
This makes polymer degradation particularly relevant when investigating:
- changes in dissolution during stability studies;
- differences between fresh and aged drug product;
- unexpected changes in viscosity or matrix erosion;
- effects of thermal or mechanical processing;
- differences between PEO batches or suppliers;
- and unexplained changes in modified-release performance.
Characterization of molecular-weight distribution together with appropriate physicochemical and dissolution measurements can help determine whether PEO degradation contributes to an observed change in drug-product performance.
Advantages and Limitations of Polyethylene Oxide in Pharmaceutical Formulations
Polyethylene oxide offers several properties that make it useful in pharmaceutical formulation development, particularly for modified- and controlled-release oral dosage forms. At the same time, its performance is highly dependent on polymer grade, formulation composition, processing and storage conditions.
Advantages of Polyethylene Oxide
PEO can provide:
- Rapid hydration and gel formation, supporting formation of a continuous hydrophilic matrix after contact with aqueous media.
- A wide molecular-weight range, allowing selection of grades with different viscosity, swelling and erosion characteristics.
- High solution viscosity at relatively low polymer concentrations for high-molecular-weight grades.
- Adjustable drug-release behaviour through selection of polymer molecular weight, polymer concentration and combinations of PEO grades.
- Good compactability and tablet-forming properties, which can support direct compression and robust matrix-tablet manufacture.
- Thermoplastic behaviour, making PEO suitable for processing approaches such as hot-melt extrusion where appropriate.
- Water solubility, avoiding the need for an insoluble polymer residue after complete matrix erosion.
- The possibility to combine PEO with other excipients to modify hydration, mechanical properties, erosion and drug release.
These properties make PEO a versatile excipient for formulations in which drug release is controlled through a combination of swelling, diffusion and polymer erosion. [5,6]
Limitations and Development Considerations
PEO also has characteristics that require careful control during pharmaceutical development. Its strong dependence on molecular weight means that polymer degradation or differences in molecular-weight distribution can alter functional performance. Oxidative chain scission during processing or storage can reduce molecular weight, potentially affecting viscosity, gel formation, erosion and dissolution. [7]
Because PEO is highly hydrophilic, its behaviour can also be sensitive to the composition of the formulation and dissolution environment. Soluble excipients, salts, drug loading, ionic strength and other formulation variables can influence hydration and polymer erosion. Performance determined with one formulation or medium should therefore not automatically be extrapolated to another.
High-molecular-weight grades can produce very viscous gels, which may be advantageous for sustained release but can also complicate processing, hydration uniformity or analytical characterization. Conversely, lower-molecular-weight grades may erode too rapidly for certain release profiles unless polymer concentration or formulation composition is adjusted.
PEO is also sensitive to thermal and oxidative stress, which is relevant during processing techniques involving heat and during long-term storage. Appropriate formulation design, processing conditions, packaging and stability evaluation may therefore be important where preservation of polymer molecular weight is critical to drug-product performance.
PEO Grade Selection Is Formulation Dependent
There is therefore no universally optimal PEO molecular weight or grade. Selection should be based on the required drug-release profile, drug properties, polymer concentration, manufacturing process and expected storage conditions.
Where unexpected differences occur between PEO grades, batches or suppliers, characterization of parameters such as molecular-weight distribution, viscosity, moisture behaviour, swelling, erosion and degradation state can help identify whether the excipient contributes to the observed formulation behaviour.
Functionality Related Characteristics (FRCs) of Polyethylene Oxide
The pharmaceutical functionality of polyethylene oxide is closely related to its molecular and physicochemical properties. Functionality Related Characteristics (FRCs) are material characteristics that may influence the ability of an excipient to perform its intended function in a particular formulation.
For PEO used as a hydrophilic matrix polymer, potentially relevant characteristics include molecular weight, molecular-weight distribution, solution viscosity, hydration rate, swelling behaviour, gel formation and polymer erosion. Particle characteristics, moisture content and thermal properties may also be relevant depending on the manufacturing process and dosage form. [3,4]
The importance of these characteristics is formulation dependent. For example, Molecular weight, molecular-weight distribution and viscosity may be particularly important where PEO controls drug release through the formation and persistence of a hydrated gel layer. Particle size and powder properties may become more relevant where blending, content uniformity or compaction are important, while thermal behaviour and polymer stability require greater attention when PEO is exposed to elevated temperatures during processing. [1,4]
Polymer degradation can itself change relevant FRCs. Oxidative chain scission can reduce molecular weight and alter the molecular-weight distribution, potentially changing viscosity, hydration, gel strength and erosion behaviour. Evaluation of PEO functionality may therefore need to consider not only the initial properties of the excipient but also whether these properties remain sufficiently stable during processing and storage.
From Pharmacopoeial Compliance to Functional Performance
Compliance with a pharmacopoeial monograph or supplier specification provides important information about the identity and quality of a PEO material, but it does not necessarily establish that different compliant materials are functionally equivalent in a particular drug product.
Two PEO batches or grades may satisfy their routine specifications while differing in characteristics that are not fully represented by those specifications. Differences in molecular-weight distribution, polymer degradation state, moisture behaviour or other physicochemical characteristics may become relevant when a formulation is sensitive to the hydration, swelling or erosion behaviour of the polymer.
The appropriate approach is therefore not to define an extensive set of additional specifications for every PEO material. Instead, the characteristics that are relevant to the intended function of PEO in the specific formulation should first be identified and understood. Where a relationship with drug-product performance can be established, selected characteristics may subsequently be used to support supplier or grade selection, batch comparison, change control or additional material specifications.
Characterizing PEO FRCs
Detailed characterization can be particularly valuable when a change in PEO supplier, grade or batch coincides with a change in manufacturing behaviour, dissolution or stability. Comparing molecular-weight distribution and complementary physicochemical properties can help determine whether differences in the polymer contribute to the observed product behaviour.
Combining PEO characterization with pharmaceutical dissolution testing is particularly powerful for modified-release formulations. Changes in the polymer can then be evaluated not only analytically but also in relation to hydration, matrix erosion and drug release. This can help distinguish a meaningful material difference from analytical variability that has no relevant effect on product performance.
Be in control of your product!
Our experts can help identify and characterize the PEO properties relevant to product performance, dissolution and stability.
Pharmacopoeial Specifications and Routine Quality Control of PEO
Polyethylene oxide used as a pharmaceutical excipient is subject to pharmacopoeial and supplier specifications intended to establish its identity, purity and general quality. Depending on the applicable compendial standard and PEO grade, testing may address characteristics such as identification, solution viscosity, pH, loss on drying or water content, residue on ignition and specified impurities or other quality attributes.
For high-molecular-weight PEO, solution viscosity is an important routine quality-control parameter because it is strongly related to polymer molecular weight. Commercial pharmaceutical grades are commonly differentiated using viscosity ranges measured at defined polymer concentrations and temperatures. Such measurements provide a practical means of controlling grade consistency and detecting substantial changes in polymer properties.
However, viscosity is an indirect and integral measurement of the polymer population. It does not provide the molecular-weight distribution itself and cannot show how different molecular-weight fractions contribute to the measured value. Two PEO materials that comply with the same viscosity range may therefore not necessarily have identical molecular-weight distributions.
Routine quality-control testing also does not directly characterize properties such as hydration rate, swelling, gel-layer development and polymer erosion. These properties arise from the interaction between the polymer, formulation and aqueous environment and can be particularly important when PEO functions as a matrix-forming excipient in a modified-release drug product.
Pharmacopoeial testing should therefore be regarded as the foundation for establishing appropriate excipient quality rather than as a complete characterization of PEO functionality. Where drug-product performance is sensitive to polymer behaviour, complementary characterization may be required to understand material differences that are not apparent from routine Certificate of Analysis data.
Molecular Weight, Viscosity and Routine Specifications
For PEO, the relationship between molecular weight and viscosity deserves particular attention. An observed change in viscosity can indicate a change in polymer molecular characteristics, including changes resulting from polymer-chain degradation. Conversely, compliance with a specified viscosity range does not establish that the complete molecular-weight distribution has remained unchanged.
Size-exclusion chromatography can complement viscosity measurements by providing information on the distribution of polymer chain sizes. This can be useful when comparing suppliers, grades or batches, investigating polymer degradation, or determining whether an unexpected change in formulation or dissolution behaviour is associated with a change in the PEO material.
The need for such additional testing should be determined by the intended pharmaceutical function and associated risk. A PEO characteristic that is important for one modified-release formulation may have little relevance in another application. Routine specifications and additional characterization should therefore be interpreted in the context of the function the polymer is required to perform.
Compendial Compliance Versus Functional Equivalence
Pharmacopoeial compliance is essential for establishing the appropriate quality of pharmaceutical PEO, but compliance does not necessarily demonstrate functional equivalence between different PEO materials. Two grades, suppliers or batches can meet the applicable compendial and supplier specifications while still differing in material characteristics that influence their behaviour in a formulation.
This distinction is particularly relevant for PEO because its pharmaceutical functionality is strongly dependent on polymer molecular characteristics. Materials with comparable nominal molecular weight and solution viscosity may differ in molecular-weight distribution, while differences in degradation state, moisture behaviour, particle characteristics or thermal history may provide additional sources of variability.
Such differences do not automatically result in different drug-product performance. Their significance depends on the formulation and the intended function of the polymer. However, in a modified-release matrix where drug release depends on PEO hydration, swelling, gel formation and erosion, relatively subtle differences in polymer properties may become relevant.
This can become particularly important during supplier or grade changes, qualification of alternative materials, batch-to-batch investigations, formulation troubleshooting and stability investigations. In these situations, comparison based solely on Certificates of Analysis may not explain an observed difference in processing or dissolution behaviour.
Additional characterization can then be used to determine whether the materials are analytically distinguishable and, more importantly, whether the identified differences are relevant to pharmaceutical performance. Techniques such as SEC for molecular-weight distribution, together with viscosity and appropriate physicochemical measurements, can provide a more detailed material fingerprint. Where necessary, these data can be combined with swelling, erosion or dissolution studies to establish whether a material difference has a meaningful effect on the drug product.
For PEO, the objective of characterization beyond compendial testing is therefore not simply to generate more analytical data, but to establish the relationship between material properties, polymer functionality and drug-product performance.
Polyethylene Oxide Characterization Services
Excipia provides specialized polyethylene oxide (PEO) analysis and characterization to support pharmaceutical formulation development, supplier and grade selection, batch comparison, troubleshooting and investigations of drug-product performance.
PEO functionality depends strongly on its molecular characteristics. Routine specifications such as nominal grade and solution viscosity provide important quality information, but they may not fully describe differences in molecular weight, molecular-weight distribution and degradation state. More detailed characterization can therefore be useful when apparently comparable PEO materials behave differently during processing, hydration or dissolution.
Size-exclusion chromatography (SEC) can be used to compare the molecular-weight distribution of PEO grades, suppliers and batches and to investigate shifts in polymer molecular weight resulting from degradation. SEC data can be interpreted together with viscosity and other physicochemical measurements to provide a more complete understanding of the polymer than either parameter alone.
Characterization can also address properties related to the pharmaceutical function of PEO, including moisture behaviour, hydration, swelling, gel formation, polymer erosion and thermal characteristics, depending on the formulation and development question.
For modified-release products, characterization of the PEO material can be combined with dissolution testing and analysis of polymer behaviour during dissolution. This allows differences in polymer properties to be investigated in relation to matrix hydration, erosion and drug release rather than considering the excipient independently from the finished dosage form.
Detailed PEO characterization can support the identification of Functionality Related Characteristics (FRCs) and, where scientifically justified, the establishment of additional material specifications. This can be particularly valuable when qualifying an alternative supplier or grade, investigating batch-to-batch variability, assessing changes during stability studies or troubleshooting unexpected changes in dissolution performance.
Through the combination of Excipia’s excipient characterization capabilities and Avivia’s formulation, analytical and dissolution expertise, PEO can be evaluated from the material level through to its impact on drug-product performance.
When Can More Detailed PEO Characterization Help?
Routine specifications may be sufficient when a polyethylene oxide material is well established and the formulation performs consistently. More detailed characterization becomes valuable when differences in PEO need to be understood in relation to manufacturing, stability or drug-product performance.
A change in PEO supplier, grade or batch may require comparison beyond nominal molecular weight and viscosity, particularly for formulations in which polymer hydration, swelling and erosion contribute directly to drug release. Characterization of molecular-weight distribution and complementary physicochemical properties can help establish whether apparently comparable materials are genuinely similar in characteristics relevant to their intended function.
Detailed characterization can also support investigations when dissolution behaviour changes unexpectedly. By combining polymer characterization with dissolution testing, differences in drug release can be evaluated together with changes in PEO molecular weight, hydration or erosion behaviour. This can help determine whether the polymer itself contributes to the observed difference or whether another formulation or process variable is responsible.
PEO characterization may also be useful during stability investigations. Oxidative chain scission can reduce polymer molecular weight and alter molecular-weight distribution, potentially changing viscosity, gel-layer behaviour and erosion even though the amount and identity of PEO in the formulation remain unchanged.
During formulation development, characterization can support selection between PEO grades or combinations of different molecular weights and help identify the material characteristics associated with the required release profile. Where such relationships are demonstrated, they can provide a scientific basis for defining additional specifications or Functionality Related Characteristics (FRCs).
Finally, detailed PEO analysis can support reference-product characterization and deformulation, particularly when the presence and approximate amount of PEO are known but its molecular characteristics or functional grade need to be understood.
Case Study: Linking PEO Release to Dissolution Performance
In a pharmaceutical development study, the behaviour of PEO in modified-release tablets was investigated by combining dissolution testing with SEC-RI analysis of the polymer released from the dosage form. The objective was to understand changes in drug-release behaviour that had developed during storage.
PEO release was followed over 24 hours for an originator product and experimental formulations containing different formulation components. Initially, the formulations and originator showed broadly comparable PEO release, with approximately 27–36% of the PEO released after 24 hours. After four weeks of storage, substantially faster polymer release was observed, reaching approximately 55% for one formulation and 94% for another.
SEC with refractive-index detection was used to examine the PEO present in the dissolution samples. Comparison of the chromatographic profiles showed that changes in polymer-release behaviour could be investigated together with differences in the PEO peak shape and chromatographic profile. For one formulation, the PEO profile changed during storage, although the observed chromatographic shift could not by itself explain the substantially faster release.
The investigation illustrates an important principle in troubleshooting PEO-containing modified-release products: drug dissolution alone may not reveal why release behaviour has changed. Measuring release of the matrix-forming polymer and characterizing the released PEO can provide an additional dimension for investigating interactions between polymer properties, formulation composition, storage and drug-product performance.
This type of combined approach can be particularly useful when conventional material specifications do not explain a change in dissolution and the role of the PEO matrix itself needs to be investigated.
What Is the Difference Between Polyethylene Oxide (PEO) and Polyethylene Glycol (PEG)?
Polyethylene oxide (PEO) and polyethylene glycol (PEG) have the same basic chemical repeat structure, –(CH₂–CH₂–O)ₙ–, and both are produced from ethylene oxide. The distinction between the names is primarily associated with molecular weight and conventional usage rather than a fundamentally different polymer structure.
In pharmaceutical applications, the term polyethylene glycol (PEG) is generally used for lower- and intermediate-molecular-weight materials, whereas polyethylene oxide (PEO) is commonly used for much higher-molecular-weight polymers. The terminology is not defined by a single universal molecular-weight boundary, so some overlap in naming can occur between suppliers, literature sources and applications.
This difference in molecular weight leads to substantial differences in pharmaceutical functionality. PEG grades are commonly used as solvents, plasticizers, lubricants, carriers, bases and processing aids, depending on molecular weight and physical form. High-molecular-weight PEO, in contrast, develops high solution viscosity and pronounced hydration, swelling, chain entanglement and gel-forming behaviour.
These properties make PEO particularly useful as a hydrophilic matrix-forming polymer in modified- and controlled-release dosage forms, where drug release can be governed by a combination of diffusion through the hydrated polymer layer and erosion of the polymer matrix.
The distinction is also important analytically. For PEO, characteristics such as molecular-weight distribution, viscosity, polymer degradation, swelling and erosion can be particularly relevant to pharmaceutical performance. For PEG, characterization may place greater emphasis on molecular-weight distribution, physicochemical properties and, where relevant, oxidative degradation and reactive impurities such as peroxides, aldehydes and organic acids.
Therefore, although PEG and PEO belong to the same polyether family, their typical pharmaceutical functions and the material characteristics requiring control can be quite different.
Frequently Asked Questions About Pharmaceutical PEO
What is the difference between polyethylene oxide (PEO) and polyethylene glycol (PEG)?
PEO and PEG have the same basic polyether repeat structure, –(CH₂–CH₂–O)ₙ–, but the terms are conventionally associated with different molecular-weight ranges and pharmaceutical applications. PEG generally refers to lower- and intermediate-molecular-weight materials, whereas PEO is commonly used for much higher-molecular-weight polymers. High-molecular-weight PEO shows pronounced hydration, swelling, gel formation and matrix-forming behaviour, making it particularly useful in modified-release formulations.
How does PEO molecular weight affect drug release?
PEO molecular weight influences solution viscosity, polymer-chain entanglement, swelling, gel-layer formation and erosion. Higher-molecular-weight PEO generally forms more persistent hydrated polymer networks and erodes more slowly, whereas lower-molecular-weight PEO can disentangle and dissolve more readily. The resulting effect on drug release also depends on drug solubility, PEO concentration, formulation composition and dosage-form properties.
Can PEO materials with similar viscosity behave differently?
Potentially. Solution viscosity is an important routine characteristic of PEO but does not completely describe the polymer population. Materials with similar viscosity specifications may differ in molecular-weight distribution, degradation state or other physicochemical characteristics. Whether such differences affect pharmaceutical performance depends on the formulation and the intended function of PEO.
Why does molecular-weight distribution matter for pharmaceutical PEO?
Commercial PEO contains polymer chains with a distribution of molecular weights rather than chains of one identical length. The relative amounts of shorter and longer chains can influence chain entanglement, hydration, swelling, dissolution and erosion. Size-exclusion chromatography (SEC) can therefore provide information about PEO that is not available from nominal molecular weight or viscosity alone.
How does PEO control drug release from matrix tablets?
When a PEO matrix contacts an aqueous medium, the polymer hydrates, swells and forms a viscous gel layer. Drug release can then occur through a combination of drug diffusion through the hydrated polymer, polymer swelling and relaxation, and erosion or dissolution of the matrix. The relative importance of these mechanisms depends on the PEO grade, polymer concentration, drug properties, formulation composition and dissolution conditions.
Can PEO degrade during pharmaceutical processing or storage?
Yes. PEO is susceptible to oxidative degradation and polymer-chain scission, which can reduce molecular weight and alter the molecular-weight distribution. Heat, oxygen, light, certain metal ions and processing conditions can contribute to degradation. Because PEO functionality is strongly molecular-weight dependent, degradation may affect viscosity, gel formation, erosion and potentially drug-release behaviour.
When is PEO characterization beyond the Certificate of Analysis useful?
More detailed characterization can be useful when comparing suppliers, grades or batches, qualifying an alternative material, investigating unexpected dissolution or manufacturing behaviour, evaluating changes during stability studies, or troubleshooting a modified-release formulation. Depending on the question, molecular-weight distribution, viscosity, moisture behaviour, swelling, erosion, thermal properties and polymer degradation can be evaluated and related to drug-product performance.
Selected Literature
1. Körner A, Larsson A, Andersson Å, Piculell L. Swelling and polymer erosion for poly(ethylene oxide) tablets of different molecular weights and polydispersities. Journal of Pharmaceutical Sciences. 2010;99(3):1225–1238. doi:10.1002/jps.21892.
2. Maggi L, Segale L, Torre ML, Ochoa ME, Conte U. Dissolution behaviour of hydrophilic matrix tablets containing two different polyethylene oxides (PEOs) for the controlled release of a water-soluble drug. Dimensionality study. Biomaterials. 2002;23(4):1113–1119. doi:10.1016/S0142-9612(01)00223-X.
3. Draksler P, Mikac U, Laggner P, Paudel A, Janković B. Polyethylene oxide matrix tablet swelling evolution: The impact of molecular mass and tablet composition. Acta Pharmaceutica. 2021;71(2):215–243. doi:10.2478/acph-2021-0018.
4. Draksler P, Janković B, Abramović Z, Lavrič Z, Meden A. Assessment of critical material attributes of polyethylene oxide for formulation of prolonged-release tablets. Drug Development and Industrial Pharmacy. 2019;45(12):1949–1958. doi:10.1080/03639045.2019.1689991.
5. Ma L, Deng L, Chen J. Applications of poly(ethylene oxide) in controlled release tablet systems: a review. Drug Development and Industrial Pharmacy. 2014;40(7):845–851. doi:10.3109/03639045.2013.831438.
6. Vanza JD, Patel RB, Dave RR, Patel MR. Polyethylene oxide and its controlled release properties in hydrophilic matrix tablets for oral administration. Pharmaceutical Development and Technology. 2020;25(10):1169–1187. doi:10.1080/10837450.2020.1808015.
[7] Shojaee S, Nokhodchi A, Maniruzzaman M. Evaluation of the drug solubility and rush ageing on drug release performance of various model drugs from the modified release polyethylene oxide matrix tablets. Drug Delivery and Translational Research. 2017;7(1):111–124. doi:10.1007/s13346-016-0344-5.
Welcome to Excipia, a service platform of Avivia, dedicated to the composition, quality and quantity of excipients in medicinal products.
Discover our unique services such as quantitative excipient analysis, identification, selection or specific formulation development support. Don’t forget to check out our case studies.
Feel free to contact us using the “Contact” button or by sending a message to Excipia@avivia.nl.
Menno Wiltink
Founder of Excipia.
